In contrast, the VERTIS CV (Evaluation of Ertugliflozin efficacy and safety cardiovascular outcomes trial in type 2 diabetes) trial did not reflect similar benefits with Ertugliflozin, nonetheless it continued to show that SGLT2 inhibitors were safe in these individuals (37). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.